Fertility
Chain IVF clinics increase access to treatment and enhance outcomes

Corporate chain ownership of fertility clinics not only increases access to treatment but also enhances patient outcomes, a new study shows.
The study shows that chain-owned clinics perform 27.2 per cent more IVF cycles and achieve a 13.6 per cent improvement in success rates. They also adopt standardised practices that reduce risky multiple births while prioritising healthier single births.
The study provides a data-driven perspective on how corporate healthcare ownership can benefit patients in an industry often characterised by competition and transparency.
“This flips the script on what we often hear about corporate healthcare,” explains Julia Bodner, study authors and a professor at Copenhagen Business School.
“In areas like nursing homes or dialysis centres, chain ownership often puts profits over patients. But in fertility clinics, it’s a different story – big companies actually make patient outcomes better by sharing resources and expertise.”
Unlike other sectors of healthcare, fertility clinics operate in a competitive marketplace in which patients can compare services, quality and costs. According to the researchers, this transparency drives chain-owned clinics to enhance care standards and invest in patient outcomes.
With global fertility rates declining and demand for fertility services rising, corporate ownership offers a scalable solution to meet these challenges while maintaining a high standard of care.
“This is one of the few branches of medicine where the free market is really working in favour of patients,” adds Ambar La Forgia, a co-author and professor in the Haas School of Business at the University of California, Berkeley.
“We’re seeing companies invest in quality because it’s what keeps patients coming through the door.”
The study also highlights the profound human impact behind the data. For many patients, these improved outcomes mean the realisation of lifelong dreams.
“At the end of the day, this isn’t just about statistics or economics – it’s about giving people the chance to build families they’ve dreamed of,” says Bodner. “Every successful treatment is a life changed, a new hope realised and a future reimagined.”
Fertility
Gum disease may impair female fertility and egg quality – study
Fertility
AI could transform ovarian care through personalisation, study finds

AI could transform ovarian care by personalising cancer and fertility treatment, but more clinical validation is needed before routine use.
A systematic review and meta-analysis found AI models showed high diagnostic accuracy for ovarian cancer when combining data such as ultrasound scans and blood test results.
Across 81 studies, AI models correctly identified ovarian cancer in around nine out of 10 cases, with pooled rates of 89 to 94 per cent.
They were also highly accurate at ruling out ovarian cancer when it was not present, with specificity of 85 to 91 per cent.
The analysis also found that explainable AI tools could predict complete surgical cytoreduction in advanced ovarian cancer.
Complete surgical cytoreduction means removing all visible cancer during surgery, which can be an important goal in treatment planning.
The tools achieved a pooled AUC of 0.87. AUC is a measure of how well a model distinguishes between different outcomes, with higher scores showing stronger performance.
In reproductive medicine, AI algorithms helped physicians optimise ovarian stimulation protocols and predict follicular growth during IVF.
Ovarian stimulation is the use of hormones to encourage the ovaries to produce eggs, while follicles are the small sacs in the ovaries where eggs develop.
The review found AI could reliably model ovarian response in IVF with a pooled AUC of 0.81.
However, researchers said challenges remain in translating promising research findings into routine clinical practice.
They identified substantial variation across studies, driven by retrospective study designs, variable AI systems and a lack of standardised validation.
Only 22 per cent of analysed studies reported prospective, multicentre external validation, where models are tested forward in time across multiple healthcare settings.
The authors called for rigorous validation to help close the gap between research and routine clinical practice, alongside standardised methodological and reporting frameworks, smooth integration with clinical workflow and robust governance to support responsible and ethical AI use.
They concluded: “Artificial intelligence is a transformative force in the management of ovarian conditions.
“In gynaecologic oncology, AI enhances every phase of care, from early detection and accurate diagnosis to prognostic stratification and surgical planning.”
In reproductive medicine, AI personalises ovarian stimulation and refines the diagnosis of heterogenous endocrine disorders such as PCOS.
PCOS, or polycystic ovary syndrome, is a hormonal condition that can affect periods, skin, weight and fertility.
Mental health
Housing, work and fertility stop Britons having the families they want – research
Opinion4 weeks agoWhat Maternal Mental Health Month reveals about where postpartum support actually breaks down
News3 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Menopause5 days agoPerimenopause misinformation ‘putting women at risk’
Adolescent health3 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Insight3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Events4 weeks agoWHIS 2026 unveils agenda and first speakers for the leading women’s health summit
Menopause3 weeks agoCBT shows promise for menopause insomnia and hot flashes
Mental health4 weeks agoOnline abuse and deepfakes ‘pushing women out of public life’














